WASHINGTON--(BUSINESS WIRE)--Today, the Biotechnology Industry Organization (BIO) released a first-of-its-kind study on venture financing broken down by disease area and novelty of research over a ten-year period from 2004 to 2013.
“Since venture financing is the lifeblood of our industry, we wanted to better understand trends in venture financing over the last decade by conducting the broadest, most comprehensive study possible,” said Cartier Esham, PhD, Executive Vice President of Emerging Companies. “The aim was to identify funding trends for emerging drug developers within specific therapeutic areas and across varying levels of innovation.”
Help employers find you! Check out all the jobs and post your resume.
